Isogeneic MSC application in a rat model of acute renal allograft rejection modulates immune response but does not prolong allograft survival

Transplant Immunology

Volumn 29, Issue 1-4, 2013, Pages 43-50

  Koch, M ^a   Lehnhardt, A ^a   Hu, X ^a   Brunswig Spickenheier, B ^a   Stolk, M ^b   Brocker V ^c   Noriega, M ^a   Seifert, M ^b   Lange, C ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Allograft rejection; Immune modulation; Kidney transplantation; Mesenchymal stromal cell; Side effect

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; CREATININE; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; GENE EXPRESSION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOCHEMISTRY; IMMUNOMODULATION; ISOGENEIC MESENCHYMAL STEM CELL TRANSPLANTATION; ISOGRAFT; KIDNEY ABSCESS; KIDNEY ALLOGRAFT REJECTION; KIDNEY INFARCTION; KIDNEY TRANSPLANTATION; LUNG INFARCTION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; RAT; SURVIVAL PREDICTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UPREGULATION;

ALLOGRAFT REJECTION; HEMOLYTIC UREMIC SYNDROME; HIGH POWER FIELD; HPF; HUS; IMMUNE MODULATION; KIDNEY TRANSPLANTATION; MESENCHYMAL STROMAL CELL; MESENCHYMAL STROMAL CELLS; MSCS; RENAL TRANSPLANTATION; RTX; SCR; SERUM CREATININE; SIDE EFFECT; THROMBOTIC MICROANGIOPATHY; TMA;

ALLOGRAFTS; ANIMALS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY TRANSPLANTATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; RATS;

EID: 84897065609     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.08.004     Document Type: Article

References (37)

1. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
2. Haynesworth S.E., Baber M.A., Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166:585-592.
3. Koc O.N., Lazarus H.M. Mesenchymal stem cells: heading into the clinic. Bone Marrow Transplant 2001, 27:235-239.
4. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
5. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
6. Le Blanc K., Samuelsson H., Gustafsson B., Remberger M., Sundberg B., Arvidson J., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21:1733-1738.
7. Uccelli A., Moretta L., Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006, 36:2566-2573.
8. Crop M., Baan C., Weimar W., Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int 2009, 22:365-376.
9. Reinders M.E., Fibbe W.E., Rabelink T.J. Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation. Nephrol Dial Transplant 2010, 25:17-24.
10. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010, 5:e10088.
11. Lange C., Togel F., Ittrich H., Clayton F., Nolte-Ernsting C., Zander A.R., et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005, 68:1613-1617.
12. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-F42.
13. Togel F.E., Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 2010, 6:179-183.
14. Ge W., Jiang J., Baroja M.L., Arp J., Zassoko R., Liu W., et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009, 9:1760-1772.
15. Inoue S., Popp F.C., Koehl G.E., Piso P., Schlitt H.J., Geissler E.K., et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006, 81:1589-1595.
16. Tan J., Wu W., Xu X., Liao L., Zheng F., Messinger S., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012, 307:1169-1177.
17. Perico N., Casiraghi F., Gotti E., Introna M., Todeschini M., Cavinato R.A., et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 2013, 26:867-878.
18. Perico N., Casiraghi F., Introna M., Gotti E., Todeschini M., Cavinato R.A., et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011, 6:412-422.
19. Jaquet K., Krause K.T., Denschel J., Faessler P., Nauerz M., Geidel S., et al. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism?. Stem Cells Dev 2005, 14:299-309.
20. Seifert M., Stolk M., Polenz D., Volk H.D. Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front Immunol 2012, 3:202.
21. Poehnert D., Broecker V., Mengel M., Nashan B., Koch M. Induction of chronic renal allograft dysfunction in a rat model with complete and exclusive MHC incompatibility. Transpl Immunol 2010, 22:137-143.
22. Koch M., Joosten S.A., Mengel M., van Kooten C., Paul L.C., Nashan B. Adoptive transfer of primed CD4+ T-lymphocytes induces pattern of chronic allograft nephropathy in a nude rat model. Transplantation 2005, 79:753-761.
23. Sis B., Mengel M., Haas M., Colvin R.B., Halloran P.F., Racusen L.C., et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010, 10:464-471.
24. Solez K., Colvin R.B., Racusen L.C., Haas M., Sis B., Mengel M., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008, 8:753-760.
25. Doege C., Koch M., Heratizadeh A., Sotonyi P., Mengel M., Nashan B. Chronic allograft nephropathy in athymic nude rats after adoptive transfer of primed T lymphocytes. Transpl Int 2005, 18:981-991.
26. Grinyó J.M., Bestard O., Torras J., Cruzado J.M. Optimal immunosuppression to prevent chronic allograft dysfunction. Kidney Int Suppl 2010, 119:S66-S70.
27. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009, 69:2227-2243.
28. De Martino M., Zonta S., Rampino T., Gregorini M., Frassoni F., Piotti G., et al. Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation. Transplant Proc 2010, 42:1331-1335.
29. Schrepfer S., Deuse T., Reichenspurner H., Fischbein M.P., Robbins R.C., Pelletier M.P. Stem cell transplantation: the lung barrier. Transplant Proc 2007, 39:573-576.
30. Forslow U., Blennow O., LeBlanc K., Ringden O., Gustafsson B., Mattsson J., et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2012, 89:220-227.
31. Moll G., Rasmusson-Duprez I., von Bahr L., Connolly-Andersen A.M., Elgue G., Funke L., et al. Are therapeutic human mesenchymal stromal cells compatible with human blood?. Stem Cells 2012, 30:1565-1574.
32. Casiraghi F., Azzollini N., Todeschini M., Cavinato R.A., Cassis P., Solini S., et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012, 12:2373-2383.
33. Gao J., Dennis J.E., Muzic R.F., Lundberg M., Caplan A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001, 169:12-20.
34. Popp F.C., Eggenhofer E., Renner P., Slowik P., Lang S.A., Kaspar H., et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008, 20:55-60.
35. Eggenhofer E., Renner P., Soeder Y., Popp F.C., Hoogduijn M.J., Geissler E.K., et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011, 25:141-147.
36. Franquesa M., Herrero E., Torras J., Ripoll E., Flaquer M., Goma M., et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012, 21:3125-3135.
37. Reinders M.E., de Fijter J.W., Roelofs H., Bajema I.M., de Vries D.K., Schaapherder A.F., et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013, 2:107-111.